Customize your JAMA Network experience by selecting one or more topics from the list below.
Hydralazine Lupus Syndrome Associated with a Possible Antihydralazine Antibody
William I. Heine, M.D., and Herman Friedman, Ph.D., PhiladelphiaSYSTEMIC LUPUS ERYTHEMATOSUS (SLE) is a disease thought to have a possibly hypersensitivity or immunologic basis. Patients with SLE show a spectrum of antinucleoprotein antibodies which may be detected by the LE cell test and by serological procedures.1 Attention has been called to the apparent production of SLE by an ever-increasing number of commonly used drugs.2,3 Included among these are hydralazine hydrochloride, penicillin, phenylbutazone, sulfadiazine, methylphenylethylhydantoin, trimethadione, and sulphamethothoxypyridazine.Hydralazine hydrochloride ( 1-hydrazinophthalazine) was introduced in 1951 for the treatment of hypertension. Beginning in 1954, there have been numerous reports4-10 of the occurrence of a lupuslike syndrome (hydralazine lupus syndrome) in about 10% of patients receiving hydralazine hydrochloride, usually after a year or more of daily doses exceeding 400 mg. The concept that SLE is associated with development of autoantibodies
Clinical Science. JAMA. 1962;182(7):726–729. doi:10.1001/jama.1962.03050460018005
Coronavirus Resource Center
Create a personal account or sign in to: